What Has Been the Progress and Growth of the Upstream Bioprocessing Market in Recent Years?
The upstream bioprocessing market has seen considerable growth due to a variety of factors.
• The upstream bioprocessing market has experienced rapid growth in recent years. It will expand from $12.03 billion in 2024 to $13.66 billion in 2025, at a CAGR of 13.6%.
The growth is attributed to the need for process optimization and contamination-free production of biomolecules, commercial success and rising demand for bio-therapeutics, implementation of process analytical technology, growing prevalence of chronic diseases, and increased research into biosimilars.
What Can Be Expected from the Upstream Bioprocessing Market Size?
The upstream bioprocessing market is expected to maintain its strong growth trajectory in upcoming years.
• The upstream bioprocessing market is projected to reach $22.43 billion by 2029, with a CAGR of 13.2%.
This growth is driven by the commercial use of single-use bioreactors, outsourcing of manufacturing, the rapid expansion of biopharmaceuticals, and growing partnerships. Trends include increased R&D investments, advancements in filtration technologies, and new upstream bioprocessing techniques.
What Are the Critical Driver Fuelling The Upstream Bioprocessing Market's Growth?
The anticipated growth of the upstream bioprocessing market is set to be driven by the outsourcing of biopharmaceutical manufacturing. This involves transferring sections of the production process to external parties such as contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs). The main motivators behind this outsourcing are cost efficiency, a focus on main business activities, the capacity to expand production scales flexibly, access to specialized knowledge and the reduction of risk. In addition, it expedites product development in the upstream bioprocessing market by utilizing external expertise, enhancing operations, and minimizing costs. BDO USA, a firm affiliated with BDO International, forecasts that by 2025, the global mammalian capacity, estimated at around 7,500kL, will be 44% controlled by contract development, manufacturing organizations, and hybrid manufacturing companies. Consequently, the outsourcing of biopharmaceutical manufacturing is influencing the growth of the upstream bioprocessing market.
How Is The Upstream Bioprocessing Market segmented?
The upstream bioprocessing market covered in this report is segmented –
1) By Product type: Bioreactors, Fermenters, Cell Culture Media, Filters, Bags And Containers
2) By Workflow: Media Preparation, Cell Culture, Cell Separation
3) By Usage type: Single-Use, Multi-Use
4) By Mode: In House, Outsourced
5) By End User: Contract Development and Manufacturing Organization (CDMOs) Or Contract Research Organization (CROs), Research And Academic Institutes, Biopharmaceutical Companies
Subsegments:
1) By Bioreactors: Single-Use Bioreactors, Multi-Use Bioreactors
2) By Fermenters: Laboratory Fermenters, Pilot Scale Fermenters, Industrial Fermenters
3) By Cell Culture Media: Powdered Media, Liquid Media
4) By Filters: Sterile Filters, Air Filters, Capsule Filters
5) By Bags And Containers: Single-Use Bags, Bioprocess Containers, Storage Bags
Pre-Book The Upstream Bioprocessing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Upstream Bioprocessing Market?
Top firms in the field of upstream bioprocessing are prioritizing the creation of state-of-the-art bioreactors to cater to the requirements of cell culture procedures. These requirements revolve around boosting performance, adaptability, and expandability. Bioreactors hold a pivotal role in upstream bioprocessing as they facilitate the streamlined and well-regulated generation of biopharmaceuticals via cell culture and creation of biomolecules. An example of this can be seen when Cytiva, a company based in the US that supplies life science products and solutions, launched its X-platform bioreactors in April 2023. The aim was to simplify single-use upstream bioprocessing actions. The bioreactors include a tank, a cabinet assembly, and a human-computer interaction (HMI) module. This modular structure grants malleable configurations without the need for bespoke hardware or single-use bags. They are user-friendly with features such as a full-opening door, baffles and superior cable management. Furthermore, the Bioreactor Scaler tool available online assists in identifying the best parameters for effective scale-up.
Who Are the Key Players In The Upstream Bioprocessing Market?
Major companies operating in the upstream bioprocessing market are:
• Thermo Fisher Scientific Inc.
• Danaher Corp
• Merck KGaA
• GE HealthCare Technologies
• Parker Hannifin Corp
• Corning Inc.
• AGC Biologics
• Avantor
• AGC Inc.
• Boehringer Ingelheim International GmbH
• Catalent Inc.
• Sartorius AG
• Entegris Inc.
• Getinge AB
• Bio-Rad Laboratories Inc.
• Samsung Biologics Co. Ltd.
• Eppendorf AG
• Repligen Corporation
• Takara Bio Inc.
• KBI Biopharma Inc.
• Rentschler Biopharma SE
• Just Biotherapeutics Inc.
• PBS Biotech Inc.
• Stobbe Group
• Applikon Biotechnology
What Is The Most Dominant Region In The Upstream Bioprocessing Market?
North America was the largest region in the upstream bioprocessing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the upstream bioprocessing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
